News Releases

WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a

Leading pharmaceutical marketing executive joins leadership team to accelerate innovation and strengthen partnerships across the life sciences industry WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts WALTHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the

Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life

– Q1 revenue totals $19.8 million – Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively – 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million – Paid off an incremental $2.7 million in principal from term loan

Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for the first time WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare

WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and

WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30

Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions

-   Q4 revenue of $32.2 million -   Q4 gross profit increased 9% year-over-year to $24.1 million -   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively -   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

-   Q4 revenue of $32.2 million -   Q4 gross profit increased 9% year-over-year to $24.1 million -   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively -   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5,

Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness WALTHAM, Mass. , Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of